产品: BAD 抗体
货号: AF6471
描述: Rabbit polyclonal antibody to BAD
应用: WB IHC IF/ICC
反应: Human, Mouse, Rat
预测: Bovine, Horse, Sheep, Dog
分子量: 23kDa; 18kD(Calculated).
蛋白号: Q92934
RRID: AB_2835290

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
预测:
Bovine(100%), Horse(100%), Sheep(100%), Dog(100%)
克隆:
Polyclonal
特异性:
BAD Antibody detects endogenous levels of total BAD.
RRID:
AB_2835290
引用格式: Affinity Biosciences Cat# AF6471, RRID:AB_2835290.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

AI325008; BAD; BAD_HUMAN; BBC 2; BBC2; BBC6; Bcl 2 Antagonist of Cell Death; Bcl 2 Binding Component 6; BCL X / BCL 2 Binding Protein; BCL X Binding Protein; Bcl XL/Bcl 2 Associated Death Promoter; Bcl-2-binding component 6; Bcl-2-like protein 8; Bcl-XL/Bcl-2-associated death promoter; Bcl2 antagonist of cell death; BCL2 antagonist of cell death protein; BCL2 associated agonist of cell death; Bcl2 Associated Death Promoter; BCL2 binding component 6; BCL2 binding protein; Bcl2 Like 8 Protein; Bcl2-L-8; BCL2L8; Proapoptotic BH3 Only Protein;

抗原和靶标

免疫原:
Uniprot:
基因/基因ID:
表达:
Q92934 BAD_HUMAN:

Expressed in a wide variety of tissues.

描述:
The protein encoded by this gene is a member of the BCL-2 family. BCL-2 family members are known to be regulators of programmed cell death. This protein positively regulates cell apoptosis by forming heterodimers with BCL-xL and BCL-2, and reversing their death repressor activity.
序列:
MFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQEQPTSSSHHGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSWWDRNLGRGSSAPSQ

种属预测

种属预测:

score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。

Species
Results
Score
Horse
100
Bovine
100
Sheep
100
Dog
100
Pig
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - Q92934 作为底物

Site PTM Type Enzyme
M1 Acetylation
S25 Phosphorylation
S32 Phosphorylation
S34 Phosphorylation
K36 Acetylation
S71 Phosphorylation
S74 Phosphorylation Q13153 (PAK1)
S75 Phosphorylation Q9NQU5 (PAK6) , Q15349 (RPS6KA2) , Q9P1W9 (PIM2) , P31749 (AKT1) , P22612 (PRKACG) , P28482 (MAPK1) , P27361 (MAPK3) , O75582 (RPS6KA5) , Q04759 (PRKCQ) , Q13153 (PAK1) , P04049 (RAF1) , P41743 (PRKCI) , Q15418 (RPS6KA1) , P45983 (MAPK8) , Q02156 (PRKCE) , Q86V86 (PIM3) , Q15139 (PRKD1) , P17612 (PRKACA) , P22694 (PRKACB) , P51812 (RPS6KA3) , P11309 (PIM1) , O96013 (PAK4) , P15056 (BRAF) , P10398 (ARAF)
Y76 Phosphorylation
T80 Phosphorylation
S91 Phosphorylation P06493 (CDK1) , P45983 (MAPK8)
R94 Methylation
R96 Methylation
S97 Phosphorylation
S99 Phosphorylation Q9Y243 (AKT3) , P51812 (RPS6KA3) , Q04759 (PRKCQ) , Q13153 (PAK1) , P31751 (AKT2) , Q15139 (PRKD1) , P41743 (PRKCI) , P31749 (AKT1) , P15056 (BRAF) , P04049 (RAF1) , Q15418 (RPS6KA1) , Q86V86 (PIM3) , P23443 (RPS6KB1) , P17612 (PRKACA) , Q9P1W9 (PIM2) , Q02156 (PRKCE) , P11309 (PIM1) , P10398 (ARAF) , P22612 (PRKACG) , P22694 (PRKACB)
Y110 Phosphorylation
S118 Phosphorylation Q15139 (PRKD1) , Q02156 (PRKCE) , P31751 (AKT2) , Q13153 (PAK1) , Q86V86 (PIM3) , P17612 (PRKACA) , Q9P1W9 (PIM2) , P15056 (BRAF) , Q9Y243 (AKT3) , Q15349 (RPS6KA2) , P31749 (AKT1) , Q13976 (PRKG1) , P11309 (PIM1) , P10398 (ARAF) , P04049 (RAF1) , P22612 (PRKACG) , P22694 (PRKACB) , P41743 (PRKCI) , Q15418 (RPS6KA1)
S124 Phosphorylation
S128 Phosphorylation
S134 Phosphorylation Q13153 (PAK1) , P15056 (BRAF) , Q13555 (CAMK2G)
T137 Phosphorylation
T139 Phosphorylation
S146 Phosphorylation
S153 Phosphorylation P17612 (PRKACA) , O75582 (RPS6KA5) , Q15418 (RPS6KA1)
R161 Methylation

研究背景

功能:

Promotes cell death. Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX. Can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2 (By similarity). Appears to act as a link between growth factor receptor signaling and the apoptotic pathways.

翻译修饰:

Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 and Ser-134 in response to survival stimuli, which blocks its pro-apoptotic activity. Phosphorylation on Ser-99 or Ser-75 promotes heterodimerization with 14-3-3 proteins. This interaction then facilitates the phosphorylation at Ser-118, a site within the BH3 motif, leading to the release of Bcl-X(L) and the promotion of cell survival. Ser-99 is the major site of AKT/PKB phosphorylation, Ser-118 the major site of protein kinase A (CAPK) phosphorylation. Phosphorylation at Ser-99 by PKB/AKT1 is almost completely blocked by the apoptotic C-terminus cleavage product of PKN2 generated by caspases-3 activity during apoptosis.

Methylation at Arg-94 and Arg-96 by PRMT1 inhibits Akt-mediated phosphorylation at Ser-99.

细胞定位:

Mitochondrion outer membrane. Cytoplasm.
Note: Colocalizes with HIF3A in the cytoplasm (By similarity). Upon phosphorylation, locates to the cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Expressed in a wide variety of tissues.

亚基结构:

Forms heterodimers with the anti-apoptotic proteins, Bcl-X(L), Bcl-2 and Bcl-W. Also binds protein S100A10 (By similarity). The Ser-75/Ser-99 phosphorylated form binds 14-3-3 proteins (By similarity). Interacts with AKT1 and PIM3. Interacts (via BH3 domain) with NOL3 (via CARD domain); preventing the association of BAD with BCL2 (By similarity). Interacts with HIF3A (via C-terminus domain); the interaction reduces the binding between BAD and BAX (By similarity). Interacts with GIMAP3/IAN4 and GIMAP5/IAN5.

蛋白家族:

Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX for their pro-apoptotic activity and for their interaction with anti-apoptotic members of the Bcl-2 family.

Belongs to the Bcl-2 family.

研究领域

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

文献引用

1). The anti-hepatocellular carcinoma effect of Brucea javanica oil in ascitic tumor-bearing mice: The detection of brusatol and its role. Biomedicine & Pharmacotherapy, 2021 (PubMed: 33341052) [IF=7.5]

2). Study on the Mechanism of Sancao Tiaowei Decoction in the Treatment of MNNG-Induced Precancerous Lesions of Gastric Carcinoma Through Hedgehog Signaling Pathway. Frontiers in Oncology, 2022 (PubMed: 35646631) [IF=4.7]

3). Anlotinib suppresses oral squamous cell carcinoma growth and metastasis by targeting the RAS protein to inhibit the PI3K/Akt signalling pathway. Analytical Cellular Pathology, 2021 (PubMed: 34926131) [IF=3.2]

Application: WB    Species: Human    Sample: HSC-3 cells

Figure 6 Effect of anlotinib on the RAS and PI3K/Akt signalling pathways in HSC-3 cells. HSC-3 cells were treated with anlotinib for 72 hours. Total RAS, phosphorylated and total Akt, and β-actin were detected by western blotting. (a) Molecular mechanism of anlotinib in HSC-3 cell apoptosis. (b) Changes in the p-Akt/Akt ratio in apoptosis. (c) Ratio changes of RAS, PI3K, and Bad proteins in apoptosis based on quantitative results of protein expression. The data are expressed as the mean ± standard deviation of three repeats. ∗∗∗P < 0.001 compared with the control.

4). Downregulated lncRNA HOTAIR ameliorates polycystic ovaries syndrome via IGF-1 mediated PI3K/Akt pathway. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2023 (PubMed: 37356454) [IF=2.0]

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.